Evotec and Spero Therapeutics extend collaboration to develop novel antibacterials

  • Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-spero-therapeutics-extend-collaboration-to-develop-novel-antibacterials-10

    Du magst vielleicht auch